BBIO - Latest News
BridgeBio Pharma, Inc. (BBIO), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $13.44B. Beta to the broader market is 1.02.
The article list below shows the most recent BBIO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent BBIO Headlines
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
marketbeat.com - May 13, 2026
BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajector
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com - May 13, 2026
BridgeBio Pharma, Inc.
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
globenewswire.com - May 12, 2026
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret a
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
globenewswire.com - May 12, 2026
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret a
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
globenewswire.com - May 11, 2026
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p
How News Affects BBIO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track BBIO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked BBIO news questions
- What is the latest BBIO news headline?
- The most recent BBIO headline (May 13, 2026) is "BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the BBIO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What BBIO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual BBIO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.